Effect of acute and chronic simvastatin treatment on post-ischemic contractile dysfunction in isolated rat heart

Physiological Research

Volumn 57, Issue 5, 2008, Pages 793-796

  Szárszoi, Ondrej ^a,b   Maly J ^a,b   Ostadal P ^c   Netuka, I ^a,b   Besik J ^a,b   Kolar F ^b   Ostadal B ^b  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b INSTITUTE OF PHYSIOLOGY   (Czech Republic)

^c NA HOMOLCE HOSPITAL   (Czech Republic)

Author keywords

Acute and chronic treatment; Ischemia reperfusion injury; Isolated rat heart; Simvastatin

Indexed keywords

CARDIOTONIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ANIMAL; ARTICLE; CORONARY ARTERY BLOOD FLOW; DISEASE MODEL; DRUG ADMINISTRATION; DRUG EFFECT; HEART CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE PRESSURE; MALE; PATHOPHYSIOLOGY; PERFUSION; RAT; REPERFUSION INJURY; WISTAR RAT;

ANIMALS; CARDIOTONIC AGENTS; CORONARY CIRCULATION; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL REPERFUSION INJURY; PERFUSION; RATS; RATS, WISTAR; SIMVASTATIN; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 55449107744     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. BELL RM, YELLON DM: Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 41: 508-515, 2003.
2. BEŠÍK J, SZÁRSZOI O, KUNEŠ J, NETUKA I, MALÝ J, KOLÁŘ F, PIRK J, OŠŤÁDAL B: Tolerance to acute ischemia in adult male and female spontaneously hypertensive rats. Physiol Res 56: 267-274, 2007.
3. CHEN J, SHEN H, NAGASAWA Y, MITSUI K, TSURUGI K, HASHIMOTO K: Pravastatin inhibits arrhythmias induced by coronary artery ischemia in anesthetized rats. J Pharmacol Sci 103: 317-322, 2007.
4. DI NAPOLI P, ANTONIO TACCARDI A, GRILLI A, SPINA R, FELACO M, BARSOTTI A, DE CATERINA R: Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex vivo study in isolated working rat hearts. Cardiovasc Res 51: 283-293, 2001.
5. JONES SP, GIBSON MF, RIMMER DM, GIBSON TM, SHARP BR, LEFER DJ: Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol 40: 1172-1178, 2002.
6. LAZAR HL, BAO Y, ZHANG Y, BERNARD SA: Pretreatment with statins enhances myocardial protection during coronary revascularization. J Thorac Cardiovasc Surg 125: 1037-1042, 2003.
7. LEFER DJ, SCALIA R, JONES SP, SHARP BR, HOFFMEYER MR, FARVID AR, GIBSON MF, LEFER AM: HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury. FASEB J 15: 1454-1456, 2001.
8. LIPID STUDY GROUP: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339: 1349-1357, 1998.
9. MENSAH K, MOCANU MM, YELLON DM: Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten? J Am Coll Cardiol 45: 1287-1291, 2005.
10. OŠŤÁDAL P: Statins in the Therapy of Acute Coronary Syndrome. Focus on Statin Research. Nova Science Publisher, edited by WONG BA, New York, 2005.
11. SACKS FM, PFEFFER MA, MOYE LA, ROULEAU JL, RUTHERFORD JD, COLE TG, BROWN L, WARNICA JW, ARNOLD JM, WUN CC, DAVIS BR, BRAUNWALD E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335: 1001-1009, 1996.
12. SANADA S, ASANUMA H, MINAMINO T, NODE K, TAKASHIMA S, OKUDA H, SHINOZAKI Y, OGAI A, FUJITA M, HIRATA A, KIM J, ASANO Y, MORI H, TOMOIKE H, KITAMURA S, HORI M, KITAKAZE M: Optimal windows of statin use for immediate infarct limitation: 5'-nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase. Circulation 110: 2143-2149, 2004.
13. SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344: 1383-1389, 1994.
14. + channels. Coron Artery Dis 15: 53-58, 2004.
15. TIEFENBACHER CP, KAPITZA J, DIETZ V, LEE CH, NIROOMAND F: Reduction of myocardial infarct size by fluvastatin. Am J Physiol 285: H59-H64, 2003.
16. WAYMAN NS, ELLIS BL, THIEMERMANN C: Simvastatin reduces infarct size in a model of acute myocardial ischemia and reperfusion in the rat. Med Sci Monit 9: BR155-159, 2003.
17. WOLFRUM S, DENDORFER A, SCHUTT M, WEIDTMANN B, HEEP A, TEMPEL K, KLEIN HH, DOMINIAK P, RICHARDT G: Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway. J Cardiovasc Pharmacol 44: 348-345, 2004.
18. YAMAKUCHI M, GREER JJ, CAMERON SJ, MATSUSHITA K, MORRELL CN, TALBOT-FOX K, BALDWIN WM, LEFER DJ, LOWENSTEIN CJ: HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size. Circ Res 9: 1185-1192, 2005.
19. ZHENG X, HU SJ: Effects of simvastatin on cardiohemodynamic responses to ischemia-reperfusion in isolated rat hearts. Heart Vessels 21: 116-123, 2006.